CA
BIS icon

Calton & Associates’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Calton & Associates’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-156
Closed -$22K – 438
2017
Q4 		$22K Buy
+156
New +$27.7K 0.01% 868

Other funds holding BIS

HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Calton & Associates's BIS Position: Q1 2018 in Review

Calton & Associates sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2018, closing a stake of 156 shares — an estimated $22K sold.

Calton & Associates first reported a position in BIS in Q4 2017 and held it in 1 quarter. The position peaked at $22K in Q4 2017. 11 funds tracked by Wall St. Rank hold BIS as of Q1 2018.

  • Calton & Associates reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 156 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2018, an estimated $22K.
  • Calton & Associates first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's ProShares UltraShort NASDAQ Biotechnology position peaked at $22K in Q4 2017.
  • 11 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.